Determinants of the Vascular Response to Training in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT ID: NCT03774238

Last Updated: 2025-09-30

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 69 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-02-20
• Study Completion Date: 2024-11-20

Brief Summary

Vascular comorbidities constitute a major burden in COPD patients. The atherosclerosis process is preceded by the onset of an endothelial dysfunction (assessed by the flow-mediated dilatation (FMD)), which is a risk factor for later ischemic vascular complications and death. In COPD, this endothelial dysfunction could be explained by intrinsic endothelial cell properties, or the effect of a pathogenic endothelial cell microenvironment (inflammation and/or oxidative stress). Exercise training constitue a powerful stimulus for the endothelial function, and could be mediated by the mobiliaztion and function of endothelial progenitors. While exercise training is an efficient intervention in COPD patients, its vascular effect appear blunted. The endothelial function response to training has appeared heterogeneous in COPD patients, and possibly linked to the endothelial cel lesion. Thus, endothelial function (assessed by the FMD) response to exercise training would be lower in COPD patients with a baseline impairment of the their FMD. In addition, of biological and functional factors could explained the magnitude of the FMD response in COPD patients.The aim of the study are thus :

To compare the FMD change in COPD patients with FMD above (FMD+) and under the median FMD (FMD-) after 4 weeks of exercise training in the whole study population.

To compare between COPD patients FMD+, COPD patients FMD- and healthy "control" subjects, the endothelial inflammation and senescence at baseline and the endothelial progenitor mobilization and function change induced by exercise (maximal exercise test and training).

To compare between COPD patients FMD+, COPD patients FMD- and healthy "control" subjects the effect of the endothelial microenvironment on the cellular pathways regulating the endothelial function in vitro at baseline and changes after exercise training.

To test in COPD patients the association between the magnitude of the FMD changes after training and biological, functional and clinical factors (inflammation oxidative stress markers, endothelial biomarkers, pulmonary impairment and phenotype, cardiovascular risks factors, vascular function, metabolic markers, physical activity level, …)

Conditions

COPD Patients; Healthy

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

COPD patients

FMD analysis Endothelial progenitors Exercise test Exercise training

Group Type: EXPERIMENTAL

FMD analysis

Intervention Type: OTHER

Blood sample and vascular exploration.

Healthy subject

FMD analysis Endothelial progenitors Exercise test

Group Type: EXPERIMENTAL

FMD analysis

Intervention Type: OTHER

Blood sample and vascular exploration.

Interventions

FMD analysis

Blood sample and vascular exploration.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

A/ COPD patients

• age between 35 and 85 years old
• spirometry showing an FEV1/VC < lower limit of normal
• with an indication for a pulmonary rehabilitation program
• written and informed consent for this study signed by the patient

B/ Healthy subjects

• age between 35 and 85 years old
• no cardiovascular or respiratory disease
• normal spirometry

Exclusion Criteria

• Unstabilized comorbidity
• Subject in a period of exclusion relative to another protocol
• Major protected by law
• Subject participating in another research protocol
• Subject not affiliated to a social security scheme
• Pregnant or lactating woman
• Patient deprived of freedom by court or administrative order

• Minimum Eligible Age: 35 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University Hospital, Paris

OTHER

Sponsor Role: collaborator

University Hospital, Montpellier

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Fares Gouzi, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

UH Montpellier

Locations

CHU Montpellier and CHU Nimes

Montpellier, , France

University Hospital, Paris

Paris, , France

Countries

France

Other Identifiers

2018-A02886-49

Identifier Type: REGISTRY

Identifier Source: secondary_id

RECHMPL18_0439

Identifier Type: -

Identifier Source: org_study_id